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Fibroblast growth factor 23 (FGF23) is a phosphotropic hormone mainly produced by 
bone. FGF23 reduces serum phosphate by suppressing intestinal phosphate absorption 
through reducing 1,25-dihydroxyvitamin D and proximal tubular phosphate reabsorp-
tion. Excessive actions of FG23 result in several kinds of hypophosphatemic rickets/
osteomalacia including X-linked hypophosphatemic rickets (XLH) and tumor-induced 
osteomalacia. While neutral phosphate and active vitamin D are standard therapies for 
child patients with XLH, these medications have several limitations both in their effects 
and adverse events. Several approaches that inhibit FGF23 actions including anti-FGF23 
antibodies and inhibitors of FGF signaling have been shown to improve phenotypes of 
model mice for FG23-related hypophosphatemic diseases. In addition, clinical trials indi-
cated that a humanized anti-FGF23 antibody increased serum phosphate and improved 
quality of life in patients with XLH. Furthermore, circulatory FGF23 is high in patients with 
chronic kidney disease (CKD). Many epidemiological studies indicated the association 
between high FGF23 levels and various adverse events especially in patients with CKD. 
However, it is not known whether the inhibition of FGF23 activities in patients with CKD 
is beneficial for these patients. In this review, recent findings concerning the modulation 
of FGF23 activities are discussed.
Keywords: hypophosphatemia, rickets, osteomalacia, antibody, chronic kidney disease-mineral and bone 
disorder (CKD-MBD)
iNTRODUCTiON
Fibroblast growth factor 23 (FGF23) was identified as a responsible gene for autosomal dominant 
hypophosphatemic rickets (ADHR) in 2000 by positional cloning (1). FGF23 was also cloned as a 
responsible humoral factor for tumor-induced osteomalacia (TIO), a rare paraneoplastic syndrome 
(2). ADHR and TIO are diseases characterized by hypophosphatemia associated with impaired renal 
tubular phosphate reabsorption. Subsequent studies established that FGF23 is a hormone mainly 
produced by bone and regulates phosphate and vitamin D metabolism by binding to Klotho–FGF 
receptor complex (3–7). Klotho is a single membrane spanning protein. While there is also soluble 
Klotho, its role in FGF23 signaling is not clear (8). FGF23 was shown to transduce signals only in 
tissues which express membrane form Klotho (6). FGF23 reduces serum phosphate by inhibiting 
intestinal phosphate absorption through decreasing serum 1,25-dihydroxyvitamin D [1,25(OH)2D] 
level and proximal tubular phosphate reabsorption (3). Therefore, ADHR and TIO have been con-
sidered to be caused by excessive actions of FGF23. These results lead to develop a concept that the 
inhibition of FGF23 activities may be beneficial for hypophosphatemic patients caused by excessive 
actions of FGF23. Furthermore, it has been shown that FGF23 is high in patients with chronic kidney 
TABle 1 | FGF23-related hypophosphatemic diseases.
Responsible 
gene
Mutations Reference
X-linked hypophosphatemic rickets: 
XLH
PHEX Inactivating (20)
Autosomal dominant 
hypophosphatemic rickets: ADHR
FGF23 Activating (1)
Autosomal recessive 
hypophosphatemic rickets 1: ARHR1
DMP1 Inactivating (21, 22)
Autosomal recessive 
hypophosphatemic rickets 2: ARHR2
ENPP1 Inactivating (23, 24)
Osteoglophonic dysplasia FGFR1 Activating (25)
Jansen-type metaphyseal 
chondrodysplasia
PTH1R Activating (26)
Hypophosphatemia with dental 
abnormality and ectopic calcification
FAM20C Inactivating (27)
McCune-Albright syndrome GNAS1 Activating (28)
Epidermal nevus syndrome: ENS HRAS, KRAS, 
NRAS
Activating (29)
Tumor-induced osteomalacia: TIO FN-FGF1, 
FN-FGFR1
Activating (30)
Hypophosphatemia after infusion of saccharated ferric oxide, iron polymaltose, 
or ferric carboxymaltose
Biliary atresia
PHEX, phosphate-regulating gene with homologies to endopeptidases on the 
X chromosome; FGF23, fibroblast growth factor 23; DMP1, dentin matrix protein 1; 
ENPP1, ectonucleotide pyrophosphatase/phosphodiesterase 1; FGFR1, fibroblast 
growth factor receptor 1; PTH1R, parathyroid hormone 1 receptor; FAM20C, family 
with sequence similarity 20, member C; GNAS1, guanine nucleotide binding protein, 
alpha-stimulating activity polypeptide 1; HRAS, Harvey rat sarcoma viral oncogene 
homolog; KRAS, Kirsten rat sarcoma rival oncogene homolog: NRAS, neuroblastoma 
RAS viral oncogene homolog; FN, fibronectin; FGFR, FGF receptor.
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disease (CKD) and can be extremely high in some subjects with 
end-stage renal disease (ESRD) (9, 10). Circulatory FGF23 levels 
have been shown to be associated with various adverse events 
such as higher mortality, cardiovascular events, and left ven-
tricular hypertrophy, especially in subjects with CKD. However, 
it is not known whether these events are direct consequences of 
FGF23 activities (11). In this review, the significance of inhibiting 
FGF23 activities in various diseases is discussed.
FGF23-RelATeD HYPOPHOSPHATeMiC 
DiSeASeS
Chronic hypophosphatemia is an important cause for rickets and 
osteomalacia characterized by impaired mineralization of bone 
matrix. Rickets develops in children before the closure of epiphy-
seal plate and results in growth retardation and bone deformities. 
In contrast, osteomalacia in adults can cause severe muscle 
weakness and bone pain. Serum phosphate level is maintained 
by intestinal phosphate absorption, renal tubular phosphate 
handling and equilibrium between extracellular phosphate and 
phosphate in bone or intracellular fluid. Of these, renal phosphate 
handling is the main determinant of chronic serum phosphate 
level. Most phosphate filtered through glomeruli is reabsorbed 
in proximal tubules by type 2a and 2c sodium-phosphate 
cotransporters. FGF23 reduces the expression of these sodium-
phosphate cotransporters and suppresses phosphate reabsorption 
(3). At the same time, FGF23 reduces serum 1,25(OH)2D by 
modulating the expression of vitamin D-metabolizing enzymes 
(3). FGF23 suppresses the expression of CYP27B1 that encodes 
a protein responsible for the production of 1,25(OH)2D. FGF23 
also enhances CYP24A1 expression that encodes an enzyme that 
works to reduce 1,25(OH)2D level.
After the identification of FGF23, several kinds of enzyme-
linked immunosorbent assay for FGF23 have been established 
(12, 13). A part of FGF23 protein is proteolytically cleaved into 
inactive N-terminal and C-terminal fragments before or during 
the process of secretion. FGF23 level can be regulated by both 
FGF23 transcription and this posttranslational processing of 
FGF23 protein. For example, iron deficiency seems to enhance 
FGF23 production and also the processing of FGF23 protein 
(14). Therefore, FGF23 level does not always reflect the amount 
of FGF23 transcription. Intact assay using two kinds of antibodies 
that recognize N-terminal and C-terminal portions of the pro-
cessing site of FGF23 detects only full-length biologically active 
FGF23 (12). In contrast, C-terminal assay using antibodies against 
the C-terminal part of FGF23 measures both full-length and 
processed inactive C-terminal fragment of FGF23 (13). FGF23 
level measured by C-terminal assay seems to correlate with the 
amount of FGF23 transcription. Intravenous iron preparations 
inhibit gene expression of FGF23. While iron dextrane does not 
affect the cleavage of FGF23, several iron preparations such as 
iron polymaltose and iron carboxymaltose may block the cleav-
age, resulting in paradoxical hypophosphatemia (14). This two 
step regulation of FGF23 needs to be kept in mind when inter-
preting results of FGF23 levels by intact and C-terminal FGF23 
assays. Measurement of FGF23 levels in patients with chronic 
hypophosphatemia indicated that FGF23 levels are high in 
hypophosphatemic patients with ADHR and TIO by both assays 
(12, 13, 15). In contrast, FGF23 levels are low in patients with 
chronic hypophosphatemia from other causes such as vitamin 
D deficiency and Fanconi syndrome indicating that circulatory 
FGF23 level is suppressed in these patients by hypophosphatemia 
or other accompanying metabolic changes (16). From these 
results, high FGF23 in patients with chronic hypophosphatemia 
seemed to indicate that this hypophosphatemia is caused by 
excessive actions of FGF23.
In addition to patients with ADHR and TIO, FGF23 levels 
have been shown to be high in several kinds of hypophosphatemic 
diseases (Table 1). Of these, X-linked hypophosphatemic rickets 
(XLH) caused by inactivating mutations of phosphate-regulating 
gene with homologies to endopeptidases on the X chromosome 
(PHEX) is the most prevalent cause of genetic hypophosphatemic 
disease. More than three hundred kinds of mutations in PHEX 
have been assembled in a database.1 PHEX is a single membrane 
spanning protein mainly expressed in bone and teeth (17). There 
is a murine model of XLH called Hyp. Hyp mice show similar bio-
chemical features to those of patients with XLH. Genetic analysis 
indicated that there is a deletion in 3′ region of Phex gene in Hyp 
mice (18). It has been shown that Fgf23 is overexpressed in bone 
and circulatory Fgf23 is high in Hyp mice (19). Therefore, it is 
1 http://www.phexdb.mcgill.ca/.
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believed that inactivating mutations in PHEX somehow induce 
enhanced expression of FGF23 in bone and cause excessive actions 
of FGF23 in patients with XLH. Signals from FGF receptor was 
reported to be involved in the overproduction of FGF23 produc-
tion in Hyp mice (7). However, the precise detailed role of PHEX 
in the regulation of FGF23 expression needs to be established.
Mutations in dentin matrix protein 1 (DMP1) and ectonucleo-
tide pyrophosphatase/phosphodiesterase 1 (ENPP1) results in auto-
somal recessive hypophosphatemic rickets 1 and 2, respectively 
(21–24). Furthermore, mutations in several other genes have been 
shown to cause hypophosphatemic diseases with high FGF23 lev-
els (31). Inactivating mutations in FAM20C was reported in Raine 
syndrome, a usually lethal osteosclerotic disease (32). However, 
hypophosphatemia with high FGF23 was later reported in some 
surviving patients (27). Osteoglophonic dysplasia is caused acti-
vating mutations in FGF receptor 1. Hypophosphatemia with high 
FGF23 in this disease again suggests the involvement of signals 
from FGF receptor in FGF23 production (25). Epidermal nevus 
syndrome is caused by somatic mutations in RAS oncogenes 
and is characterized by sebaceous nevi and skeletal defects (29). 
These oncogene products can transduce signals from receptor 
tyrosine kinases including FGF receptor. Jansen-type metaphy-
seal chodrodysplasia and McCune-Albright syndrome are caused 
by activating mutations in parathyroid hormone (PTH) 1 receptor 
and GNAS1, respectively (26, 28). These results suggest that cyclic 
AMP pathway is involved in FGF23 production. In some patients 
with TIO, FN (fibronectin)-FGF receptor 1 or FN-FGF1 fusion 
gene was reported in responsible tumors (30). It is likely that these 
genes activate some intracellular signaling pathway to enhance 
FGF23 production.
In addition to diseases with known genetic causes, hypophos-
phatemia with high FGF23 has been reported in patients 
receiving some intravenous iron preparations (33, 34). Recently, 
it has been reported that biliary atresia can be associated with 
hypophosphatemia with high FGF23 (35). In most of these 
FGF23-related hypophosphatemic diseases, FGF23 is considered 
to be overexpressed in bone while the detailed mechanism of this 
overproduction is not clear. On the contrary, in patients with TIO, 
the responsible tumors produce FGF23 and FGF23 is shown to 
be expressed in liver in a patient with biliary atresia. Collectively, 
these results indicate that excessive production and actions of 
FGF23 can cause several kinds of hypophosphatemic diseases.
THe iNHiBiTiON OF FGF23 ACTiviTY AS A 
New THeRAPeUTiC MANeUveR FOR 
FGF23-RelATeD HYPOPHOSPHATeMiC 
DiSeASeS
Direct FGF23 Targeting
Tumor-induced osteomalacia is a paraneoplastic syndrome and 
can be cured by complete resection of the responsible tumors. 
However, it is sometimes difficult to find the responsible tumors 
in patients with TIO. Even when the responsible tumors can 
be found, it is not always possible to completely remove the 
lesions. For those patients with TIO whose responsible tumors 
cannot be removed, neutral phosphate and active vitamin D are 
usually prescribed. For patients with most other FGF23-related 
hypophosphatemic diseases including XLH, the same drugs are 
also used. However, these medications are not drugs based on the 
pathophysiology of these diseases. In addition, these medications 
may not able to correct impaired growth completely in patients 
with hypophosphatemic rickets (36). Furthermore, administra-
tion of phosphate and active vitamin D can be associated with 
several adverse events such as hypercalcemia, hypercalciuria, 
nephrocalcinosis, and gastrointestinal symptoms (37).
It has been shown that excessive activities of FGF23 underlie 
the pathogenesis of FGF23-related hypophosphatemic diseases as 
mentioned above. Therefore, the suppression of FGF23 activities 
has been considered as a novel therapy for patients with these 
diseases. Murine monoclonal antibodies against N-terminal 
and C-terminal portions of human FGF23 were obtained. These 
antibodies inhibited in  vitro FGF23 activity and synergistically 
increased serum phosphate and 1,25(OH)2D levels in normal mice 
(38). These results as well as phenotypes of hyperphosphatemia 
and high 1,25(OH)2D in Fgf23 null mice confirmed that FGF23 is 
a physiological regulator of phosphate and vitamin D metabolism 
(4, 38). Then, these antibodies were tested in Hyp mice and were 
shown to increase serum phosphate and 1,25(OH)2D (39). In 
addition, repeated administration of these antibodies enhanced 
longitudinal growth of long bones, increased bone mineral 
density and corrected impaired mineralization of Hyp mice 
(39). Furthermore, these antibodies increased grip power and 
spontaneous movement of Hyp mice (40). These results suggested 
that the inhibition of FGF23 activities by FGF23 antibodies can 
ameliorate biochemical, morphological, histological and clinical 
abnormalities of patients with FGF23-related hypophosphatemic 
rickets/osteomalacia.
Based on the results of these preclinical studies, humanized 
anti-FGF23 monoclonal antibody (burosumab) was developed 
and tested in several clinical trials. The initial phase I study 
involving 38 adult patients with XLH showed that burosumab 
increased serum phosphate, 1,25(OH)2D and tubular maximum 
transport of phosphate per glomerular filtration rate (TmP/GFR), 
an index of proximal tubular phosphate reabsorption, in a dose-
dependent manner (41). Subsequent study with 28 adult patients 
with XLH showed that subcutaneous injections of burosumab 
every 4 weeks increased serum phosphate, 1,25(OH)2D and TmP/
GFR after each administration (42). Furthermore, burosumab 
was shown to significantly improve patient perception of physical 
functioning and stiffness (43). These results indicated that buro-
sumab can improve biochemical abnormalities of adult patients 
with XLH and improve quality of life. However, it was unclear 
from these studies whether burosumab can also work in children 
and ameliorate rickets/osteomalacia.
While the results have not yet been published as articles so 
far, several clinical trials with burosumab are ongoing. Results 
presented in several scientific meetings and available on the web 
suggest that burosumab can improve biochemical abnormalities 
in child patients with XLH and also in patients with TIO.2,3 In 
addition, burosumab seems to improve roentgenological signs of 
2 http://www.ultragenyx.com/pipeline/krn23-xlh/.
3 http://www.ultragenyx.com/pipeline/krn23-tio/.
4Fukumoto New Treatment by Inhibition of FGF23 Actions
Frontiers in Endocrinology | www.frontiersin.org February 2018 | Volume 9 | Article 48
rickets in children. Based on these results, the US Food and Drug 
Administration granted a Breakthrough Therapy Designation for 
burosumab in 2016 (see footnote 2). However, there are several 
questions to be answered in the future studies. Long-term safety 
should be carefully monitored. In addition, it has not yet been 
shown whether burosumab can heal rickets/osteomalacia and 
normalize height in child patients with XLH. Furthermore, it has 
not been established how long burosumab should be used for 
child patients with XLH. Theoretically, burosumab seems to be 
effective in patients with other FGF23-related hypophosphatemic 
diseases than XLH and TIO. This also needs to be proved in the 
future trials. Collectively, burosumab has been shown to inhibit 
FGF23 actions in human and seems to be promising as a novel 
therapy for patients with FGF23-related hypophosphatemic 
diseases.
In addition to anti-FGF23 antibody, a computationally identi-
fied compound binding to FGF23 was also shown to increase 
serum phosphate and 1,25(OH)2D in a model mouse of FGF23-
related hypophosphatemic diseases (44). These compounds can 
be cost-effective compared to the antibody. However, this small 
molecule has not been used in clinical trials.
Klotho–FGF Receptor Complex Targeting
Another approach is to inhibit the binding of FGF23 to Klotho–
FGF receptor complex. Purified C-terminal fragment of FGF23 
protein was shown to compete with full-length FGF23 for the 
binding to Klotho–FGF receptor complex (45). Administration 
of this C-terminal fragment of FGF23 temporally increased 
serum phosphate of Hyp mice (45). The C-terminal portion of 
FGF23 protein was fused to Fc portion of IgG1 to increase the 
stability of the C-terminal fragment (46). This FGF23 c-tail-Fc 
fusion molecule also increased serum phosphate and improved 
mineralization of Hyp mice when repeatedly injected (46). In 
addition to this C-terminal fragment of FGF23, several small 
compounds were shown to impair the interaction between FGF23 
and Klotho–FGF receptor complex (47).
Targeting FGF Receptor
In addition, the inhibition of FGF receptor was shown to inhibit 
FGF23 activities (48, 49). Several reports suggest that signals 
from FGF receptor stimulate FGF23 production in bone (7, 
48). Therefore, it is possible that the inhibition of FGF recep-
tor suppresses both the production and the actions of FGF23. 
NVP-BGJ398, a pan FGF receptor inhibitor, increased serum 
phosphate, enhanced bone growth, increased mineralization, and 
corrected the disturbed growth plate structure in Hyp mice (49).
Targeting of Downstream Signals from 
FGF Receptor
The inhibition of mitogen-activated protein kinase (MAPK) path-
way was also shown to impair FGF23 actions while FGF receptor 
can activate several signal transduction pathways. PD0325901, 
an inhibitor of MAPK pathway, was shown to increase serum 
phosphate and 1,25(OH)2D, and correct impaired mineralization 
in Hyp mice (50). These preclinical studies indicated that there are 
several ways to inhibit excessive FGF23 activities causing FGF23-
related hypophosphatemic diseases.
However, FGF receptor-MAPK pathway is involved in numer-
ous biological processes in addition to mediating FGF23 actions 
suggesting that the inhibition of this pathway can be associated 
with various adverse events. NVP-BGJ398 and PD0325901 
have been tested in several clinical trials mainly for patients 
with solid cancers.4 NVP-BGJ398 was shown to inhibit FGF23 
secretion in patients with TIO caused by malignant tumors 
(51). However, these inhibitors have not yet tested for patients 
with genetic FGF23-related hypophosphatemic diseases or TIO 
caused by benign tumors. FGF23 c-tail-Fc fusion molecule and 
other small compounds that impair the binding of FGF23 to 
Klotho–FGF receptor complex have not been tested in clinical 
trials, either.
FGF23 AND CKD-MBD
Circulatory FGF23 level is high in patients with CKD. Several 
studies indicated that FGF23 starts to increase in the early phase 
of CKD (10, 52). This increase of FGF23 precedes those of PTH 
and phosphate. While the detailed regulatory mechanisms of 
FGF23 production and circulatory FGF23 levels remain to be 
clarified, 1,25(OH)2D and high phosphate diet were shown to 
enhance FGF23 levels (53). However, in patients with early CKD 
with high FGF23 level, 1,25(OH)2D and phosphate are not high. 
Recent studies suggest that inflammation and iron deficiency are 
involved in this high FGF23 in patients with CKD (54).
In a model rat of early CKD, the inhibition of Fgf23 activ-
ity by anti-FGF23 antibodies were shown to enhance proximal 
tubular phosphate reabsorption and increase serum phosphate 
and 1,25(OH)2D (55). These results suggest that high FGF23 in 
patients with early CKD suppresses phosphate reabsorption and 
works to prevent the development of hyperphosphatemia. The 
inhibition of Fgf23 activities by anti-FGF23 antibody in a model 
rat of CKD was also shown to cause higher mortality by increas-
ing serum phosphate and promoting ectopic calcification (56). 
Therefore, this increase of FGF23 in patients with early CKD is 
considered to be one of adaptive responses to maintain mineral 
homeostasis.
In contrast, there are now many epidemiological studies that 
indicate the association between high FGF23 levels and various 
adverse events especially in patients with CKD or ESRD (11). For 
example, high FGF23 levels in patients who were beginning hemo-
dialysis were shown to be associated with higher mortality during 
the first year of hemodialysis (57). Adverse events associated with 
high FGF23 are quite diverse including cardiovascular events, left 
ventricular hypertrophy, progression of CKD, fractures, higher 
mortality, frailty, insulin resistance, and so on. These associations 
suggest that the inhibition of FGF23 activity may be beneficial in 
patients with CKD under certain conditions. Actually, secondary 
analysis of Evaluation Of Cinacalcet Hydrochloride Therapy to 
Lower CardioVascular Events indicated that cinacalcet-induced 
reductions in serum FGF23 were associated with lower rates 
of cardiovascular death and major cardiovascular events (58). 
However, there has been no study that examined effects of 
4 https://clinicaltrials.gov/ct2/home.
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inhibiting FGF23 activities by anti-FGF23 antibody or inhibitors 
in patients with ESRD. In addition, the reason for the associa-
tion between high FGF23 levels and various adverse events are 
not clear enough. While it was reported that FGF23 signals in 
a Klotho-independent fashion through FGFR4/nuclear factor of 
activated T  cells/calcineurin, which may cause left ventricular 
hypertrophy (59, 60), it has not been shown how FGF23 can 
activate FGF receptor without Klotho. In addition, it is not clear 
either whether FGF23 induces various adverse events directly 
working on several tissues like heart, bone and kidney. Further 
studies are necessary to establish the usefulness of inhibiting 
FGF23 activities in patients with CKD.
CONClUSiON
Fibroblast growth factor 23 is a hormone that reduces serum 
phosphate and 1,25(OH)2D levels. For patients with excessive 
hormone actions, therapeutic measures to suppress the activities 
of that hormone are used. Therefore, it is reasonable to develop 
methods to inhibit FGF23 actions for patients with FGF23-related 
hypophosphatemic diseases. Patients with hypophosphatemic 
disorders by FGF23 excess may benefit from FGF23 blocking 
antibodies or inhibitors of FGF23 signaling. However, these 
therapies need careful monitoring because deficient actions of 
FGF23 result in hyperphosphatemic disease. On the contrary, 
FGF23 seems to be high in response to changes of mineral 
homeostasis or other metabolic process in patients with CKD. 
Patients with CKD may benefit from these novel therapies to the 
extent that FGF23 secretion is excessively stimulated and beyond 
what’s needed in compensation. However, there is not enough 
evidence that indicates the inhibition of FGF23 activities is useful 
for patients with CKD.
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